ABOUT YPSOMED
Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid injectable medications. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.
INDUSTRY INSIGHTS
-
![Story Behind MIDBA]( "The Story Behind MIDBA: An Exclusive Interview")
A new regulatory framework reduces PK bridging study needs, helping sponsors streamline device transitions, lower costs, speed up timelines, and boost regulatory predictability for combination products.
-
![GettyImages-1209427002 biopharm]( "Navigating Large-Volume Subcutaneous Biologic Injections")
Large-volume subcutaneous delivery is bringing biologic treatments closer to patients. Learn how advances in dosing and device technology are shaping care.
-
![injectables-syringe-GettyImages-2098817477]( "High-Dose Delivery: Integration And Performance")
High-viscosity therapies bring new delivery challenges. Explore how needle, syringe, and device design affect injection performance, reliability, and user experience.
-
![injectables-regulatory-GettyImages-2248556042]( "The Regulatory Compass Driving Drug Delivery Innovation")
Regulatory requirements are growing more complex. Discover how strategic planning, regulatory intelligence, and platform approaches can streamline development and approvals.
-
![clinical-trial-tech-GettyImages-2249359887]( "Insights From DPHARM: Reimagining The Future Of Connected Clinical Trials")
Connected technologies are enabling smarter clinical trials. Discover how remote data capture and decentralized approaches can reduce burden and improve patient engagement.
-
![autoinjectables-clinical-GettyImages-2197657107]( "MIDBA: A New Regulatory Approach To Clinical Device Bridging")
When devices evolve, evidence expectations can shift. Explore a risk-based clinical bridging approach to support regulatory decisions.
-
![Team collaboration, planning for property development-GettyImages-1796900872]( "Flying On Two Wings: Balancing Local Agility And Global Quality In China")
As China expands its role in drug development, injectable therapy programs face new demands. Learn how manufacturers are scaling quality, devices, and production for global success.
CONTACT INFORMATION
Ypsomed
Headquarters Burgdorf Brunnmattstrasse 6
Burgdorf, 3401
SWITZERLAND
SOLUTIONS
-
![LSC 09.26 Newsletter Ypsomed Fig 1]( "Connected Solutions For Self-Injection")
From enabling connected clinical trials to supporting digital therapy management, our solutions help improve clinical trial operational efficiency and data quality, strengthen commercial success, and empower patients to self-manage their therapy.
